Gender differences regarding interest in opioid agonist treatment with hydromorphone: a cross-sectional study of syringe service program participants

In the United States, only 15–20% of people with opioid use disorder (OUD) receive medications for OUD annually. Injectable opioid agonist treatment with hydromorphone (iOAT-H) is a novel approach that reduces…

Read the full article ›